Innoviva saw the highest growth of 1.99% in patent filings in May and 2.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Innoviva‘s patent filings and grants. Buy the databook here.
Innoviva has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 33% filings and 17% grants. The South Korea(KR), China(CN), Denmark(DK), and Australia(AU) patent Office are among the top ten patent offices where Innoviva is filings its patents. Among the top granted patent authorities, Innoviva has 17% of its grants in South Korea(KR), 17% in Australia(AU) and 17% in European Patent Office(EPO).
Roche could be the strongest competitor for Innoviva
Patents related to rare diseases and climate change lead Innoviva's portfolio
Innoviva has the highest number of patents in rare diseases followed by, climate change and healthtech. For rare diseases, nearly 100% of patents were filed and 40% of patents were granted in Q2 2024.
Hypotension related patents lead Innoviva portfolio followed by liver cirrhosis, and renal failure
Innoviva has highest number of patents in hypotension followed by liver cirrhosis, renal failure.
For comprehensive analysis of Innoviva's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.